The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
ORGANIZATION
FPMAJ Poll Finds Worsening Supply Woes with 28% of Drugs Restricted or Suspended
Japan’s drug supply disruptions appear to be deteriorating as the number of suspended products rose in the wake of GMP violations, with the shipments of over 28.2% of listed medicines found to be restricted or stopped, according to an industry…
To read the full story
Related Article
- Shipments Curbed or Suspended for 22.9% of Products in September: FPMAJ
October 27, 2023
- Shipments Restricted or Halted for 22.9% of Products in August: FPMAJ
September 25, 2023
- Shipments Restricted or Suspended for 22.4% of Products in July, No Sign of Improvement: FPMAJ
August 31, 2023
- Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
July 24, 2023
- Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
May 24, 2023
- Over 20% of All Generics under Restricted Shipments: FPMAJ
March 14, 2023
- FPMAJ Calls on Drug Makers to Lift Shipment Controls of 233 APIs/Specifications
December 28, 2022
- 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
ORGANIZATION
- Gap between Poll Results and Drug Availability “Inevitable,” FPMAJ Says after JMA’s Criticism
November 22, 2023
- New Group Led by MRI to Issue Clinical Trial Policy Proposals by September 2024
November 22, 2023
- Israel-Palestine Conflict to Have Limited Impact on Japan Pharma Sector for Now: JPMA
November 17, 2023
- JPMA Gearing Up for Drug Pricing Reform Debate towards December: Exec
November 17, 2023
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…